drugset / Trial / NCT07091370
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Timeline
- Start
- 2025-12-27
- Primary completion
- 2026-09-30
- Completion
- 2028-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inaticabtagene autoleucel | Cell therapy | 0.25 cells/kg | — |
| Subject | Inaticabtagene autoleucel | Cell therapy | 0.5 cells/kg | — |
| Subject | Inaticabtagene autoleucel | Cell therapy | 1 cells/kg | — |
| Subject | Inaticabtagene autoleucel | Cell therapy | 1.5 cells/kg | — |